Welcome to our dedicated page for Codexis news (Ticker: CDXS), a resource for investors and traders seeking the latest updates and insights on Codexis stock.
Codexis, Inc. develops enzyme-based solutions for therapeutics manufacturing, using its CodeEvolver technology to discover and improve high-performance enzymes. Company news commonly covers financial results, guidance, cash-runway commentary, and business updates tied to small molecule pharmaceutical biocatalysis, nucleic acid synthesis, and the ECO Synthesis manufacturing platform for enzymatic RNAi and siRNA production.
Recurring developments include partner and evaluation agreements, technology-transfer activity, quality-system and manufacturing-suite updates, conference data on ECO Synthesis capabilities such as phosphorothioate stereochemistry and ligation efficiency, and portfolio updates for enzymes used in branded pharmaceutical products.
Codexis (NASDAQ: CDXS) reported fourth-quarter revenue of $38.9M and fiscal 2025 total revenue of $70.4M. The company ended 2025 with $78.2M in cash and expects runway through 2027. Fiscal 2025 saw product gross margin of 64% and a net loss of $44.0M.
Q4 growth was driven by a $37.8M Technology Transfer Agreement with Merck and momentum in ECO Synthesis commercial engagements; the company provided 2026 revenue guidance of $72M–$76M.
Codexis (NASDAQ: CDXS) announced on March 4, 2026 an agreement to manufacture 50 grams of small interfering RNA (siRNA) using its proprietary ECO Synthesis manufacturing platform to support a partner's preclinical cardiovascular program.
The engagement is presented as a demonstration of the platform's ability to produce material beyond early research volumes and as a potential pathway to further scale-up and commercial manufacturing, subject to program advancement.
Codexis (NASDAQ: CDXS) will report fourth quarter and fiscal year 2025 results on Wednesday, March 11, 2026 after market close. Management will host a conference call and webcast at 4:30 PM ET to discuss results and provide a business update.
The live webcast will be available on the Codexis Investor Relations website and archived for 90 days; a telephone replay will be available for 48 hours.
Codexis (NASDAQ: CDXS) will attend the TD Cowen 46th Annual Health Care Conference in Boston March 2-4, 2026. Management will join a fireside chat on March 3, 2026 at 11:50 am ET. A live webcast will be available on the company's Investor Relations site and replayed for 90 days.
Codexis (Nasdaq: CDXS) announced it earned ISO 9001:2015 certification on February 10, 2026, covering its Redwood City headquarters, R&D, process development labs including the ECO Synthesis Innovation Laboratory, and its non‑GMP manufacturing facility.
The certification recognizes Codexis’s documented quality management system for design, development, manufacturing, delivery, and support, and signals a commitment to continuous quality improvement in its biomanufacturing products and services.
Codexis (NASDAQ: CDXS) and Axolabs announced an evaluation agreement dated January 7, 2026, under which Axolabs will test Codexis' ECO Synthesis Manufacturing Platform for enzymatic RNA/oligonucleotide production.
The agreement gives Axolabs access to Codexis' scalable enzymatic synthesis technology and may lead to future licensing discussions and broader platform adoption if evaluation results are favourable. Both companies described the collaboration as advancing efficient, sustainable manufacturing of oligonucleotide therapeutics and expanding access to high-quality oligonucleotide medicines.
Codexis (NASDAQ: CDXS) signed a lease for a 34,000 square foot GMP manufacturing facility in Hayward, California to expand internal GMP production capabilities.
The multi-purpose site will enable GMP manufacturing of siRNA and other oligonucleotides using the company's ECO Synthesis platform, start modifications in early 2026, and can be adapted to scale production of purified enzymes that support the platform. The company said the facility will support early clinical trial manufacturing and provide flexible capacity for evolving business needs.
Codexis (NASDAQ: CDXS) reported Q3 2025 results and a business update on Nov 6, 2025. Key items include a $37.8M Supply Assurance Agreement with Merck (cash expected by year‑end), organizational changes including a CEO transition, elimination of 46 positions (~24% workforce) and an expected $3.5M charge in Q4 2025. Management said these actions extend the company’s cash runway bthrough 2027$58.7M as of Sept 30, 2025.
Codexis (NASDAQ: CDXS) and Nitto Denko Avecia announced an evaluation agreement dated Oct. 29, 2025 for Codexis' ECO Synthesis® Manufacturing Platform. Under the agreement, Nitto Denko Avecia will evaluate the enzyme‑catalyzed ECO Synthesis approach that replaces traditional solid‑phase oligonucleotide synthesis.
The collaboration is intended to enable future licensing discussions and broader adoption of the platform, and to explore scalable, sustainable manufacturing for therapeutic siRNA by combining Codexis' enzymatic technology with Nitto Denko Avecia's CDMO expertise.
Codexis (NASDAQ: CDXS) will report third quarter 2025 financial results on Thursday, November 6, 2025, after market close. Management will host a conference call and live webcast at 4:30 PM Eastern Time to discuss results and provide a business update.
Investors can access the live webcast on the Codexis Investor Relations website; the webcast will be archived for 90 days. A telephone replay will be available for 48 hours with access ID 13726635.